Abstract library

21 results for "Rita".
#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Daneng Li
Authors: Li D, Imbesi G, Yen L, Kim H, ...
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#116 Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma
Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Vanessa Capitanio
Authors: Capitanio V, Papa M, Zerbi A, Vitali G, ...
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Takuji Okusaka
Authors: Okusaka T, Ito T, Ikeda M, Tajima T, ...
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Conference:
Category: Clinical
Presenting Author: Antongiulio Faggiano
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo
#780 Epigenetic Regulation of Endogenous Somatostatin Expression in Neuroendocrine Tumors
Introduction: Somatostatin (SST) can regulate hormone secretion and cell proliferation in neuroendocrine tumors (NETs). SST expression levels in NETs likely differ between patients. DNA methylation inhibits gene transcription and can be reversed by the demethylating drug 5-aza-2-deoxycytidine (AZA).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: MSc Marije J. Veenstra
#894 The Effects of cAMP in Different Neuroendocrine Tumorous Cells: The Role of Epac and PKA in Cell Proliferation and Cell Adhesion
Introduction: cAMP is implicated in the inhibition or stimulation of proliferation depending on cell type. Although the effects exerted by cAMP were initially attributed to the PKA activation, two cAMP-activated guanine nucleotide exchange (Epac1/2) have been later identified as cAMP targets.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Eleonora Vitali
Keywords: cAMP, PKA, EPAC, GEP-NET
#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MSc Marije J Veenstra
Keywords: GEP-NET, sst2, epigenetics
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno